CO6440515A2 - Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b - Google Patents
Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3bInfo
- Publication number
- CO6440515A2 CO6440515A2 CO11150255A CO11150255A CO6440515A2 CO 6440515 A2 CO6440515 A2 CO 6440515A2 CO 11150255 A CO11150255 A CO 11150255A CO 11150255 A CO11150255 A CO 11150255A CO 6440515 A2 CO6440515 A2 CO 6440515A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- compositions
- methods
- directed
- complement protein
- Prior art date
Links
- 102000000989 Complement System Proteins Human genes 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 108010069112 Complement System Proteins Proteins 0.000 title 1
- 108010078015 Complement C3b Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17586009P | 2009-05-06 | 2009-05-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6440515A2 true CO6440515A2 (es) | 2012-05-15 |
Family
ID=43063291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11150255A CO6440515A2 (es) | 2009-05-06 | 2011-11-04 | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20100291106A1 (enExample) |
| EP (1) | EP2427491A2 (enExample) |
| JP (1) | JP2012525829A (enExample) |
| KR (1) | KR20120088551A (enExample) |
| CN (1) | CN102459334A (enExample) |
| AR (1) | AR076655A1 (enExample) |
| AU (1) | AU2010252156A1 (enExample) |
| CA (1) | CA2760757A1 (enExample) |
| CL (1) | CL2011002756A1 (enExample) |
| CO (1) | CO6440515A2 (enExample) |
| EA (1) | EA201101593A1 (enExample) |
| EC (1) | ECSP11011445A (enExample) |
| IL (1) | IL216061A0 (enExample) |
| MA (1) | MA33402B1 (enExample) |
| MX (1) | MX2011011754A (enExample) |
| PE (1) | PE20120899A1 (enExample) |
| SG (1) | SG175432A1 (enExample) |
| TN (1) | TN2011000528A1 (enExample) |
| TW (1) | TW201043638A (enExample) |
| UY (1) | UY32612A (enExample) |
| WO (1) | WO2010136311A2 (enExample) |
| ZA (1) | ZA201107551B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005107708A1 (en) | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase inhibitors implants |
| BRPI0712987A2 (pt) | 2006-06-21 | 2012-04-10 | Musc Found For Res Dev | tratamento de doenças direcionado ao fator h do complemento |
| AU2010266127B2 (en) | 2009-07-02 | 2015-11-05 | Musc Foundation For Research Development | Methods of stimulating liver regeneration |
| WO2011057158A1 (en) | 2009-11-05 | 2011-05-12 | Taligen Therapeutics, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis |
| SG185483A1 (en) | 2010-05-14 | 2012-12-28 | Univ Colorado Regents | Improved complement receptor 2 (cr2) targeting groups |
| CN103249432A (zh) | 2010-06-22 | 2013-08-14 | 科罗拉多大学董事会,法人团体 | 补体成分3的C3d片段的抗体 |
| US8940490B2 (en) * | 2010-11-29 | 2015-01-27 | Novelmed Therapeutics, Inc. | Neoantibodies for diagnosing tissue injury |
| CN104220453B (zh) * | 2012-04-03 | 2018-03-09 | 诺沃姆德治疗公司 | 人源化的嵌合抗因子c3抗体及其用途 |
| AU2013302441B2 (en) | 2012-08-17 | 2018-05-10 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
| US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
| CN104870475B (zh) | 2012-10-25 | 2019-11-08 | 美国比奥维拉迪维股份有限公司 | 抗补体C1s抗体和其用途 |
| US8945562B2 (en) | 2012-11-02 | 2015-02-03 | True North Therapeutics, Inc. | Anti-complement C1s antibodies |
| HK1215174A1 (zh) * | 2012-11-29 | 2016-08-19 | Bayer Healthcare Llc | 針對活化蛋白c的人源化單克隆抗體及其用途 |
| US20160051673A1 (en) | 2013-03-29 | 2016-02-25 | Alexion Pharmaceuticals, Inc. | Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5 |
| US20150079613A1 (en) | 2013-08-07 | 2015-03-19 | Ryan Kitchel | Atypical hemolytic uremic syndrome biomarker proteins |
| EP3054965B1 (en) * | 2013-10-07 | 2021-04-14 | Massachusetts Eye & Ear Infirmary | Anti-factor d antibody for use in preventing or reducing retinal detachment |
| EP3086809A4 (en) | 2013-12-24 | 2017-11-29 | NovelMed Therapeutics, Inc. | Compositions and methods of treating ocular diseases |
| AU2015223056B2 (en) | 2014-02-27 | 2020-10-01 | Allergan, Inc. | Complement Factor Bb antibodies |
| US11077187B2 (en) | 2015-11-17 | 2021-08-03 | Oklahoma Medical Research Foundation | Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof |
| PE20191031A1 (es) | 2016-10-12 | 2019-08-05 | Bioverativ Usa Inc | ANTICUERPOS ANTI-C1s Y METODOS DE USO DE LOS MISMOS |
| WO2018075474A1 (en) | 2016-10-17 | 2018-04-26 | Medical University Of South Carolina | Compositions and methods for treating central nervous system injury |
| BR112020019907A2 (pt) * | 2018-04-03 | 2021-01-05 | Ngm Biopharmaceuticals, Inc. | Agentes de ligação a c3 e métodos de uso dos mesmos |
| EP4257602A3 (en) | 2018-06-11 | 2023-12-27 | Aarhus Universitet | Single domain antibodies for complement regulation |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| EP4308609A4 (en) * | 2021-03-19 | 2025-06-04 | Elpis Biopharmaceuticals | Antibodies specific to sialic acid-binding ig-like lectin 15 and uses thereof |
| WO2024108529A1 (en) * | 2022-11-25 | 2024-05-30 | Linno Pharmaceuticals Inc. | Properdin binding protein and use thereof |
| CN118434764A (zh) | 2021-12-22 | 2024-08-02 | Cdr生物科技股份有限公司 | 抗c3抗体及其抗原结合片段及其用于治疗眼疾病的用途 |
| KR20230105972A (ko) | 2022-01-05 | 2023-07-12 | 주식회사 카나프테라퓨틱스 | 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도 |
| CN114874329A (zh) * | 2022-05-19 | 2022-08-09 | 江苏大学 | 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用 |
| TW202417510A (zh) * | 2022-09-20 | 2024-05-01 | 美商威特拉公司 | 用ｃ３ｂ抗體治療補體介導之疾病及病症 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE452065B (sv) * | 1986-04-11 | 1987-11-09 | Ulf R Nilsson | Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DK2026073T3 (en) * | 2000-04-29 | 2016-07-25 | Univ Iowa Res Found | Diagnosis and treatment of macular degeneration-related disorders |
| US7838165B2 (en) * | 2004-07-02 | 2010-11-23 | Kabushiki Kaisha Toshiba | Carbon fiber synthesizing catalyst and method of making thereof |
| WO2006012621A2 (en) * | 2004-07-23 | 2006-02-02 | University Of Virginia Patent Foundation | Compositions and methods for regulating the alternative pathway of complement |
| US20090191217A1 (en) * | 2004-12-02 | 2009-07-30 | De Wildt Ruud M | Anti-IL-1R1 Single Domain Antibodies And Therapeutic Uses |
| AR055191A1 (es) * | 2005-10-12 | 2007-08-08 | Morphosys Ag | Generacion y caracterizacion de anticuerpos terapeuticos derivados de hucal- gold totalmente humanos especificos para el cd38 humano |
| GB0613209D0 (en) * | 2006-07-03 | 2006-08-09 | Ucb Sa | Methods |
| US8192742B2 (en) * | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
| KR101572700B1 (ko) * | 2007-06-07 | 2015-11-30 | 제넨테크, 인크. | 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법 |
| AR069130A1 (es) * | 2007-11-02 | 2009-12-30 | Novartis Ag | Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento |
-
2010
- 2010-05-04 US US12/773,246 patent/US20100291106A1/en not_active Abandoned
- 2010-05-05 JP JP2012509035A patent/JP2012525829A/ja active Pending
- 2010-05-05 KR KR1020117029046A patent/KR20120088551A/ko not_active Withdrawn
- 2010-05-05 AR ARP100101527A patent/AR076655A1/es not_active Application Discontinuation
- 2010-05-05 WO PCT/EP2010/056129 patent/WO2010136311A2/en not_active Ceased
- 2010-05-05 CA CA2760757A patent/CA2760757A1/en not_active Abandoned
- 2010-05-05 SG SG2011080330A patent/SG175432A1/en unknown
- 2010-05-05 AU AU2010252156A patent/AU2010252156A1/en not_active Abandoned
- 2010-05-05 MA MA34415A patent/MA33402B1/fr unknown
- 2010-05-05 EP EP10747599A patent/EP2427491A2/en not_active Withdrawn
- 2010-05-05 TW TW099114417A patent/TW201043638A/zh unknown
- 2010-05-05 PE PE2011001908A patent/PE20120899A1/es not_active Application Discontinuation
- 2010-05-05 EA EA201101593A patent/EA201101593A1/ru unknown
- 2010-05-05 MX MX2011011754A patent/MX2011011754A/es not_active Application Discontinuation
- 2010-05-05 CN CN201080026538XA patent/CN102459334A/zh active Pending
- 2010-05-06 UY UY0001032612A patent/UY32612A/es not_active Application Discontinuation
-
2011
- 2011-10-14 ZA ZA2011/07551A patent/ZA201107551B/en unknown
- 2011-10-19 TN TNP2011000528A patent/TN2011000528A1/en unknown
- 2011-10-31 IL IL216061A patent/IL216061A0/en unknown
- 2011-11-04 CL CL2011002756A patent/CL2011002756A1/es unknown
- 2011-11-04 CO CO11150255A patent/CO6440515A2/es not_active Application Discontinuation
- 2011-11-08 EC EC2011011445A patent/ECSP11011445A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102459334A (zh) | 2012-05-16 |
| ECSP11011445A (es) | 2012-01-31 |
| JP2012525829A (ja) | 2012-10-25 |
| ZA201107551B (en) | 2012-07-25 |
| MX2011011754A (es) | 2011-11-29 |
| EA201101593A1 (ru) | 2012-06-29 |
| US20100291106A1 (en) | 2010-11-18 |
| CA2760757A1 (en) | 2010-12-02 |
| CL2011002756A1 (es) | 2012-03-23 |
| PE20120899A1 (es) | 2012-08-03 |
| EP2427491A2 (en) | 2012-03-14 |
| KR20120088551A (ko) | 2012-08-08 |
| IL216061A0 (en) | 2012-01-31 |
| TN2011000528A1 (en) | 2013-05-24 |
| TW201043638A (en) | 2010-12-16 |
| WO2010136311A2 (en) | 2010-12-02 |
| AR076655A1 (es) | 2011-06-29 |
| SG175432A1 (en) | 2011-12-29 |
| MA33402B1 (fr) | 2012-07-03 |
| UY32612A (es) | 2010-12-31 |
| WO2010136311A3 (en) | 2011-05-26 |
| AU2010252156A1 (en) | 2011-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP11011445A (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c3b | |
| CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
| CO7250445A2 (es) | Proteínas de unión a antígeno st2 | |
| CO6351748A2 (es) | Anticuerpos contra il-6 y sus usos | |
| CY1118014T1 (el) | Aνti-il-23 αντισωματα | |
| CR20170262A (es) | Composiciones y métodos para anticuerpos dirigidos a bmp6 | |
| CR20160206A (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5 | |
| BR112013021562A2 (pt) | anticorpos para cd70 | |
| MX357678B (es) | Moléculas de unión específica a proteína de unión a adn de respuesta transactiva de 43 kda (tdp-43). | |
| BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
| CR20110358A (es) | Proteinas de enlace de miostatina | |
| EA201400579A1 (ru) | Антитела к il-36r | |
| EA201490677A1 (ru) | Связывающие антиген cd27l белки | |
| CO6290772A2 (es) | Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos | |
| EA201591091A1 (ru) | Антигенсвязывающие белки для bcma | |
| EA201791693A1 (ru) | Гетеродимерные иммуноглобулины | |
| UY37030A (es) | Anticuerpos dirigidos a cd32b y métodos de uso de los mismos | |
| EA201491214A1 (ru) | Композиции и способы применения антител, нацеленных на фактор p | |
| EA201291065A1 (ru) | Антитела против vla-4 | |
| CL2017002705A1 (es) | Anticuerpos que se dirigen a la proteína morfogénica ósea 9 (bmp9) y a los métodos a los que se refieren | |
| BR112013007514A2 (pt) | anticorpo isolado, uso da composição e método | |
| EA201500502A1 (ru) | Связывающие антиген her3 белки, связывающиеся с бета-шпилькой her3 | |
| MX385858B (es) | Anticuerpos que se unen a notum pectinacetilesterasa. | |
| MX2015004892A (es) | Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21. | |
| AR123070A2 (es) | Anticuerpos anti-il-23 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |